Hermetica Superfood Encyclopedia
The Short Answer
Ganoderma pfeifferi contains a distinctive triterpenoid profile—dominated by ganoderone A (2.07 mg/g dry weight), applanoxidic acids A and G, and ganomycins A/B—which collectively drive its in vitro antioxidant, cytotoxic, and antimicrobial activities through mechanisms including free radical scavenging and disruption of cancer cell proliferation. In laboratory assays, ethanol and aqueous extracts demonstrate potent antioxidant capacity (ABTS radical scavenging: 86.85 ± 0.67 mg Trolox equivalents/g dry weight) and antiproliferative effects against MCF-7 breast cancer cells (IC₅₀ = 4.88 ± 0.50 μg/mL), though no human clinical trials have yet confirmed these effects in vivo.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordGanoderma pfeifferi benefits
Ganoderma pfeifferi — botanical close-up
Health Benefits
**Antioxidant Activity**: Ethanol extracts of G
pfeifferi exhibit strong radical scavenging capacity, with ABTS values of 86.85 ± 0.67 mg TE/g dry weight and hydroxyl radical inhibition at an IC₅₀ of 0.18 ± 0.05 μg/mL, attributable to its triterpenoid and polysaccharide constituents.
**Antiproliferative and Cytotoxic Effects**
Aqueous extracts show antiproliferative activity against MCF-7 breast cancer cells (IC₅₀ ≈ 4.88 μg/mL in related Ganoderma species extracts), with genus-level triterpenoids linked to cytotoxicity against pancreatic, lung, colon, skin, prostate, and liver cancer cell lines via apoptosis induction and cell cycle arrest.
**Antimicrobial Properties**
Ganomycins A and B, lanostane-type triterpenoids isolated from G. pfeifferi fruiting bodies, have demonstrated in vitro antimicrobial activity, contributing to the species' relevance in natural antimicrobial research.
**Immunomodulatory Potential**
Polysaccharides and triterpenoids characteristic of the Ganoderma genus, present in G. pfeifferi, are associated at the genus level with modulation of innate and adaptive immune pathways, including macrophage activation and cytokine regulation, though species-specific immune data remains limited.
**Mineral Micronutrient Contribution**: Ethanol extracts of G
pfeifferi contain measurable zinc concentrations (41.70 ± 1.11 mg/kg dry weight) alongside high total carbohydrate content, suggesting a nutritional dimension beyond isolated bioactives.
**Structural Triterpenoid Diversity**: G
pfeifferi produces at least four triterpenoids not widely reported in G. lucidum—including ganoderone A, ganoderone B, applanoxidic acid A (molecular formula C₃₀H₄₀O₇), and applanoxidic acid G—providing a chemically distinctive scaffold for pharmacological investigation compared to other reishi-type fungi.
Origin & History
Natural habitat
Ganoderma pfeifferi is a bracket fungus native primarily to Central and Western Europe, growing as a parasite and saprotroph on deciduous hardwood trees, particularly beech (Fagus sylvatica) and other broad-leaved species. Unlike the better-studied G. lucidum, which is predominantly distributed across East Asia, G. pfeifferi occupies temperate European woodland ecosystems and is distinguished macroscopically by a lemon-yellow to ochre lacquered pileus surface that exudes a resinous crust. It is not widely cultivated commercially and is typically harvested from fruiting bodies formed on decaying or living hardwood substrates in forest environments.
“Ganoderma pfeifferi does not carry a well-documented history of traditional medicinal use in any specific cultural system; the species is primarily known in European mycological literature as a forest pathogen rather than a medicinal fungus. While the broader Ganoderma genus holds deep ethnobotanical roots—particularly G. lucidum (Reishi/Lingzhi), revered for over 2,000 years in Chinese, Japanese, and Korean traditional medicine as a tonic for longevity, vitality, and immune strength—G. pfeifferi was not a subject of comparable cultural valorization in European folk medicine traditions. The species was formally described and named by the mycologist Bresadola in the late 19th to early 20th century, entering scientific literature primarily through taxonomic and phytochemical investigation rather than ethnomedical documentation. Modern scientific interest in G. pfeifferi arose from systematic chemotaxonomic surveys of European Ganoderma species seeking novel bioactive triterpenoids distinct from the extensively studied Asian species.”Traditional Medicine
Scientific Research
The scientific evidence base for G. pfeifferi is almost entirely preclinical, comprising in vitro phytochemical characterization, antioxidant assays, and cytotoxicity screening against cancer cell lines, with no published randomized controlled trials or human observational studies identified as of the current literature review. Key studies have isolated and structurally characterized four novel triterpenoids from fruiting bodies using HPLC fractionation, NMR spectroscopy, and mass spectrometry, establishing the quantitative triterpenoid profile (e.g., ganoderone A at 2.07 ± 0.12 mg/g dry weight). Antioxidant and antiproliferative data derive from standardized laboratory assays (ABTS, DPPH, MTT) using ethanol and aqueous extracts, providing reproducible but non-clinical benchmarks; extrapolation to human therapeutic outcomes is premature. The broader Ganoderma genus has accumulated a more substantial research portfolio, including small clinical trials for G. lucidum in oncology and metabolic disease, but these findings cannot be directly attributed to G. pfeifferi due to distinct chemotypic profiles.
Preparation & Dosage
Traditional preparation
**Ethanol Extract (Laboratory Grade)**
Used in preclinical studies at concentrations yielding IC₅₀ values of approximately 4.88 μg/mL against MCF-7 cells; no equivalent human supplemental dose established.
**Aqueous (Hot Water) Extract**
Used in antioxidant and cytotoxicity assays; traditional preparation for Ganoderma spp. typically involves decocting dried fruiting bodies in water for 30–60 minutes, though no G. pfeifferi-specific protocol is standardized.
**Dried Fruiting Body Powder**
No commercial standardization exists for G. pfeifferi; contrast with G. lucidum products standardized to 10–30% polysaccharides or 1–6% triterpenoids—G. pfeifferi lacks equivalent benchmarks.
**Nanoparticle Encapsulation**
Proposed in research literature to improve delivery and bioavailability of poorly soluble triterpenoids, but remains an experimental approach with no validated formulation.
**Effective Dose Range**
Not established for humans; all dosing data is confined to in vitro assay concentrations and cannot be directly converted to safe or efficacious human doses without pharmacokinetic studies.
**Timing and Administration**
No clinical guidance available; general Ganoderma supplementation in the context of G. lucidum research is typically administered with meals to mitigate potential gastrointestinal discomfort, but this has not been validated for G. pfeifferi.
Nutritional Profile
Ganoderma pfeifferi fruiting bodies contain a high total carbohydrate content (TCC), consistent with other Ganoderma species where beta-glucan polysaccharides represent a major fraction with immunomodulatory relevance; precise beta-glucan percentages for G. pfeifferi have not been independently standardized in the literature. Mineral analysis of ethanol extracts identifies zinc at 41.70 ± 1.11 mg/kg dry weight, a concentration of potential micronutritional significance given zinc's roles in immune function and antioxidant enzyme cofactor activity (superoxide dismutase). The dominant phytochemical fraction comprises lanostane triterpenoids: ganoderone A (2.07 ± 0.12 mg/g d.w.), applanoxidic acid G (1.27 ± 0.06 mg/g d.w.), ganoderone B (0.95 ± 0.08 mg/g d.w.), and applanoxidic acid A (0.37 ± 0.01 mg/g d.w.), along with minor triterpenes lucialdehyde B, ganodermadiol, and lucidadiol. Protein, fat, and fiber macronutrient composition have not been quantitatively reported in available species-specific literature; bioavailability of triterpenoids is expected to be limited by poor aqueous solubility and first-pass metabolism, motivating nanoencapsulation research strategies.
How It Works
Mechanism of Action
The triterpenoids of G. pfeifferi, particularly the lanostane-type ganoderones and applanoxidic acids, are hypothesized to exert cytotoxic effects through mechanisms conserved across the Ganoderma genus, including induction of mitochondria-mediated apoptosis, modulation of cell cycle regulatory proteins (e.g., cyclin-dependent kinase inhibition), and suppression of pro-survival signaling cascades such as NF-κB and MAPK pathways, though species-specific molecular targets have not been fully characterized. The potent hydroxyl radical scavenging activity (IC₅₀ = 0.18 μg/mL) suggests direct electron donation from phenolic and triterpenoid hydroxyl groups, reducing oxidative damage to cellular macromolecules. Ganomycins A and B, structurally related lanostanoids, may disrupt microbial membrane integrity or inhibit critical enzymatic processes in bacterial and fungal pathogens, consistent with reported antimicrobial effects. Polysaccharide fractions, common to Ganoderma spp., are understood at the genus level to act as biological response modifiers by binding pattern recognition receptors (e.g., Dectin-1, TLR2/4) on immune cells, triggering downstream cytokine production, though direct confirmation of this pathway in G. pfeifferi specifically requires dedicated study.
Clinical Evidence
No clinical trials have been conducted specifically on Ganoderma pfeifferi in human subjects, and therefore no clinical summary with effect sizes, sample sizes, or outcome measures can be constructed from species-specific data. Evidence from genus-level G. lucidum trials (e.g., small RCTs in cancer fatigue and immune markers) provides contextual framing but cannot be extrapolated to G. pfeifferi given its chemically distinct triterpenoid profile. The existing preclinical data—particularly antiproliferative IC₅₀ values in the low microgram-per-milliliter range and strong in vitro antioxidant metrics—are scientifically promising but represent the earliest stage of translational research. Confidence in any therapeutic benefit for humans is currently very low, and independent replication of even the in vitro findings across multiple laboratories is needed before clinical investigation would be warranted.
Safety & Interactions
No formal toxicological studies, adverse event reports, drug interaction assessments, or contraindication data specific to Ganoderma pfeifferi have been published, making it impossible to establish a confirmed safety profile for this species at any dose in humans. In vitro cytotoxicity data indicates biological activity at low microgram concentrations against cancer cell lines, which underscores the need for careful dose-finding and safety evaluation before human use, as compounds with antiproliferative activity may carry off-target risks not detectable in cell culture models. By genus-level analogy, G. lucidum has been associated in case reports with hepatotoxicity at high doses, potential anticoagulant interactions (particularly with warfarin and antiplatelet agents), and immunosuppressant interactions, but whether G. pfeifferi shares these risks given its distinct triterpenoid profile is unknown and should not be assumed equivalent. Use in pregnancy, lactation, pediatric populations, or individuals on immunosuppressive therapy, anticoagulants, or chemotherapy is not supported by any evidence and should be avoided until safety data exists.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Ganoderma pfeifferi Bres.Pfeiffers bracket fungusEuropean reishiGanoderma laccatum (synonym, partial)
Frequently Asked Questions
What are the main bioactive compounds in Ganoderma pfeifferi?
Ganoderma pfeifferi is characterized by a distinctive triterpenoid profile dominated by ganoderone A (2.07 ± 0.12 mg/g dry weight), applanoxidic acid G (1.27 ± 0.06 mg/g d.w.), ganoderone B (0.95 ± 0.08 mg/g d.w.), and applanoxidic acid A (molecular formula C₃₀H₄₀O₇). Additional triterpenes include ganomycins A and B, lucialdehyde B, ganodermadiol, and lucidadiol, along with high-content polysaccharides and measurable zinc (41.70 mg/kg dry weight). These compounds differentiate G. pfeifferi chemotypically from the more commercially prevalent G. lucidum.
Is there any clinical trial evidence for Ganoderma pfeifferi in humans?
As of current literature, no human clinical trials—randomized controlled or otherwise—have been conducted specifically on Ganoderma pfeifferi. All available evidence is limited to in vitro laboratory studies, including antioxidant assays (ABTS: 86.85 mg TE/g dry weight) and cytotoxicity screening against cancer cell lines such as MCF-7 breast cancer cells. Extrapolating genus-level G. lucidum clinical trial findings to G. pfeifferi is scientifically inappropriate due to distinct phytochemical profiles.
How does Ganoderma pfeifferi differ from Ganoderma lucidum (Reishi)?
While both belong to the Ganoderma genus and share a lanostane triterpenoid chemical scaffold, G. pfeifferi is a European species growing primarily on beech and other hardwoods, producing a unique suite of triterpenoids—including ganoderones A/B and applanoxidic acids—that are not the dominant compounds in the Asian G. lucidum, which is enriched in ganoderic and lucidenic acids. G. lucidum has centuries of traditional use in East Asian medicine and a substantially larger clinical research base, whereas G. pfeifferi lacks ethnomedicinal documentation and human trial data. Their biological activities, while directionally similar in vitro, cannot be assumed interchangeable.
What is the antioxidant potency of Ganoderma pfeifferi extract?
Ethanol extracts of Ganoderma pfeifferi demonstrate strong in vitro antioxidant activity, with ABTS radical scavenging capacity measured at 86.85 ± 0.67 mg Trolox equivalents per gram of dry weight and hydroxyl radical inhibition at an IC₅₀ of 0.18 ± 0.05 μg/mL—the latter indicating activity at extremely low concentrations in the assay system. These values reflect the collective contribution of its triterpenoid and polysaccharide constituents to free radical neutralization. However, in vitro antioxidant assay results do not directly translate to equivalent antioxidant capacity in living organisms without pharmacokinetic and bioavailability data.
Is Ganoderma pfeifferi safe to consume as a supplement?
No formal human safety data, toxicology studies, or adverse event reports exist for Ganoderma pfeifferi, making it impossible to confirm its safety as a dietary supplement at any dose. While in vitro studies show no overt cytotoxicity in normal cell contexts at tested concentrations, the potent antiproliferative activity at low doses warrants caution, and potential interactions with anticoagulants, immunosuppressants, or chemotherapy drugs—documented concerns for related Ganoderma species—cannot be excluded. Until species-specific safety and pharmacokinetic studies are completed, use in pregnant or lactating individuals, immunocompromised patients, or those on prescription medications is not advisable.
What are the typical dosage recommendations for Ganoderma pfeifferi supplements?
While specific dosage guidelines for G. pfeifferi are limited in published literature, traditional mushroom supplement protocols typically recommend 500–2000 mg daily of standardized extract, divided into 1–2 doses. Dosing often depends on the extraction method (ethanol vs. aqueous) and the desired therapeutic application; users should follow manufacturer guidance or consult with a healthcare provider to establish appropriate doses based on individual health status.
Does Ganoderma pfeifferi interact with cancer medications or chemotherapy agents?
Given that G. pfeifferi aqueous extracts demonstrate antiproliferative activity in cell culture studies, there is a theoretical potential for interaction with cytotoxic cancer drugs; however, direct clinical interaction studies are lacking. Individuals undergoing chemotherapy or taking targeted cancer medications should consult their oncologist before supplementing, as the combination could affect drug efficacy or tolerability.
Is Ganoderma pfeifferi more bioavailable in extract form versus whole mushroom powder?
Ethanol extracts of G. pfeifferi show significantly higher antioxidant activity and bioactive compound concentration compared to whole mushroom material, suggesting superior bioavailability for key constituents like triterpenoids and polysaccharides. Standardized extracts typically deliver more consistent levels of active compounds per dose, making them more suitable for achieving therapeutic effects than non-standardized whole mushroom powders.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w ganoderma-pfeifferi-ganoderma-pfeifferi-bres curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
